Investigating how NAD+ affects glioblastoma growth and treatment resistance
NAD+ Pathway Signaling in Glioblastoma Tumor Growth and Therapy Resistance
This study is looking at how a key molecule called NAD+ affects glioblastoma, a tough brain tumor, to find new ways to help treat it and improve outcomes for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10654813 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a challenging brain tumor that is difficult to treat. It explores the role of nicotinamide adenine dinucleotide (NAD+), a crucial molecule in cancer cell metabolism, and how it influences tumor growth and resistance to therapies. The study aims to uncover the mechanisms by which NAD+ impacts glioblastoma cells, particularly through a specific transcriptional program that is vital for their survival and growth. By analyzing human tumor samples and testing new treatment strategies, the research seeks to identify potential therapeutic targets for improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who are seeking new treatment options.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that improve survival rates for patients with glioblastoma.
How similar studies have performed: Other research has shown promising results in targeting metabolic pathways in cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Kim, Albert Hong-Jae — Washington University
- Study coordinator: Kim, Albert Hong-Jae
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.